


PHARMACEUTICAL 2021

ESPERION

Esperion Therapeutics Inc. Rank 231 of 409





PHARMACEUTICAL 2021

ESPERION

Esperion Therapeutics Inc. Rank 231 of 409

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 169% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 99% points.

The company's Economic Capital Ratio, given in the ranking table, is -172%, being 183% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	345,896
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	94,069
Liabilities, Non-Current	4,744
Other Assets	6,086
Other Compr. Net Income	-23
Other Expenses	25,062
Other Liabilities	350,579
Other Net Income	515
Property and Equipment	1,276
Research and Development	146,936
Revenues	227,547
Selling, General and Administrative Expense	199,615

Output Variable	Value in 1000 USD
Assets	353,258
Liabilities	449,392
Expenses	371,613
Stockholders Equity	-96,134
Net Income	-143,551
Comprehensive Net Income	-143,562
Economic Capital Ratio	-172%